Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Low neutralizing antibody titers against the Mu variant of SARS-CoV-2 in BNT162b2 vaccinated individuals

View ORCID ProfileDiego A. Álvarez-Díaz, View ORCID ProfileAna Luisa Muñoz, Pilar Tavera-Rodríguez, María T. Herrera-Sepúlveda, View ORCID ProfileHector Alejandro Ruiz-Moreno, View ORCID ProfileKatherine Laiton-Donato, View ORCID ProfileCarlos Franco-Muñoz, View ORCID ProfileDioselina Pelaez-Carvajal, Diego Cuellar, View ORCID ProfileAlejandra M. Muñoz-Ramirez, Marisol Galindo, Edgar J. Arias-Ramirez, View ORCID ProfileMarcela Mercado-Reyes
doi: https://doi.org/10.1101/2021.11.19.21266552
Diego A. Álvarez-Díaz
1Grupo Genómica de Microorganismos Emergentes. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Diego A. Álvarez-Díaz
  • For correspondence: daalvarezd@unal.edu.co
Ana Luisa Muñoz
2Fundación Banco Nacional de Sangre Hemolife, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ana Luisa Muñoz
Pilar Tavera-Rodríguez
3Dirección de Investigación en Salud Pública. Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María T. Herrera-Sepúlveda
1Grupo Genómica de Microorganismos Emergentes. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
4Grupo de Parasitología. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hector Alejandro Ruiz-Moreno
1Grupo Genómica de Microorganismos Emergentes. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hector Alejandro Ruiz-Moreno
Katherine Laiton-Donato
1Grupo Genómica de Microorganismos Emergentes. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Katherine Laiton-Donato
Carlos Franco-Muñoz
1Grupo Genómica de Microorganismos Emergentes. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
4Grupo de Parasitología. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carlos Franco-Muñoz
Dioselina Pelaez-Carvajal
1Grupo Genómica de Microorganismos Emergentes. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dioselina Pelaez-Carvajal
Diego Cuellar
3Dirección de Investigación en Salud Pública. Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alejandra M. Muñoz-Ramirez
5Dirección de Producción. Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alejandra M. Muñoz-Ramirez
Marisol Galindo
1Grupo Genómica de Microorganismos Emergentes. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edgar J. Arias-Ramirez
5Dirección de Producción. Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcela Mercado-Reyes
1Grupo Genómica de Microorganismos Emergentes. Dirección de Investigación en Salud Pública, Instituto Nacional de Salud, Bogotá, Colombia
3Dirección de Investigación en Salud Pública. Instituto Nacional de Salud, Bogotá, Colombia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marcela Mercado-Reyes
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Summary

Background Global surveillance programs for the virus that causes COVID-19 are showing the emergence of variants with mutations in the Spike protein, including the Mu variant, recently declared a Variant of Interest (VOI) by the World Health Organization. Genomic and laboratory surveillance is important in these types of variants because they may be more infectious or less susceptible to antiviral treatments and vaccine-induced antibodies.

Objectives To evaluate the sensitivity of the Mu variant (B.1.621) to neutralizing antibodies induced by the BNT162b2 vaccine.

Study design Three of the most predominant SARS-CoV-2 variants in Colombia during the epidemiological peaks of 2021 were isolated. Microneutralization assays were performed by incubating 120 TCDI50 of each SARS-CoV-2 isolate with five 2-fold serial dilutions of sera from 14 BNT162b2 vaccinated volunteers. The MN50 titer was calculated by the Reed-Muench formula

Results The three isolated variants were Mu, a Variant of Interest (VOI), Gamma, a variant of concern (VOC), and B.1.111 that lacks genetic markers associated with greater virulence. At the end of August, the Mu and Gamma variants were widely distributed in Colombia. Mu was predominant (49%), followed by Gamma (25%). In contrast, B.1.111 became almost undetectable. The evaluation of neutralizing antibodies suggests that patients vaccinated with BNT162-2 generate neutralizing antibody titers against the Mu variant at significantly lower concentrations relative to B.1.111 and Gamma.

Conclusions This study shows the importance of continuing with surveillance programs of emerging variants as well as the need to evaluate the neutralizing antibody response induced by other vaccines circulating in the country against Mu and other variants with high epidemiological impact.

Highlights

  • Mu and Gamma variants represented 49% and 25% of cases in Colombia by August 2021.

  • Increased proportion of SARS-COV-2 cases were mostly associated with Mu variant, despite being detected simultaneously with the VOC Gamma

  • The Mu variant remarkably escapes from neutralizing antibodies elicited by the BNT162b2-vaccine

  • Laboratory studies of neutralizing antibodies are useful to determine the efficacy of SARS-CoV-2 vaccines against VOC and VOI.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was funded by the Instituto Nacional de Salud project code CEMIN-04-2021 and Sistema General de Regalias (SGR) project code BPIN 2020000100151.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was approved by the Ethics Committee of the Colombian National Health Institute, (CEMIN)-04-2021, carried out in accordance with the Declaration of Helsinki. All subjects enrolled in this research responded voluntarily to an informed consent formulary.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 19, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Low neutralizing antibody titers against the Mu variant of SARS-CoV-2 in BNT162b2 vaccinated individuals
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Low neutralizing antibody titers against the Mu variant of SARS-CoV-2 in BNT162b2 vaccinated individuals
Diego A. Álvarez-Díaz, Ana Luisa Muñoz, Pilar Tavera-Rodríguez, María T. Herrera-Sepúlveda, Hector Alejandro Ruiz-Moreno, Katherine Laiton-Donato, Carlos Franco-Muñoz, Dioselina Pelaez-Carvajal, Diego Cuellar, Alejandra M. Muñoz-Ramirez, Marisol Galindo, Edgar J. Arias-Ramirez, Marcela Mercado-Reyes
medRxiv 2021.11.19.21266552; doi: https://doi.org/10.1101/2021.11.19.21266552
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Low neutralizing antibody titers against the Mu variant of SARS-CoV-2 in BNT162b2 vaccinated individuals
Diego A. Álvarez-Díaz, Ana Luisa Muñoz, Pilar Tavera-Rodríguez, María T. Herrera-Sepúlveda, Hector Alejandro Ruiz-Moreno, Katherine Laiton-Donato, Carlos Franco-Muñoz, Dioselina Pelaez-Carvajal, Diego Cuellar, Alejandra M. Muñoz-Ramirez, Marisol Galindo, Edgar J. Arias-Ramirez, Marcela Mercado-Reyes
medRxiv 2021.11.19.21266552; doi: https://doi.org/10.1101/2021.11.19.21266552

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1264)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (538)
  • Epidemiology (10056)
  • Forensic Medicine (5)
  • Gastroenterology (502)
  • Genetic and Genomic Medicine (2486)
  • Geriatric Medicine (240)
  • Health Economics (482)
  • Health Informatics (1653)
  • Health Policy (757)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (538)
  • Infectious Diseases (except HIV/AIDS) (11896)
  • Intensive Care and Critical Care Medicine (627)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2304)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1259)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2295)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (657)
  • Rheumatology (289)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (273)
  • Toxicology (44)
  • Transplantation (131)
  • Urology (100)